Qiagen NV (QGEN)

31.25
NASDAQ : Services
Prev Close 31.44
Day Low/High 31.20 / 31.44
52 Wk Low/High 24.86 / 35.26
Avg Volume 781.90K
Exchange NASDAQ
Shares Outstanding 228.23M
Market Cap 7.18B
EPS 0.30
P/E Ratio 92.47
Div & Yield N.A. (N.A)

Latest News

French Health System Approves Reimbursement Of QIAGEN's QuantiFERON Latent TB Test

Gold standard test for latent tuberculosis infection will be covered by national health insurance

QIAGEN's QuantiFERON®-TB Gold Plus Gains U.S. FDA Approval

Fourth generation Latent TB blood test combines breakthrough CD4/CD8 design for comprehensive immune response detection with the most flexible blood collection workflow

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EFII, ENBL, NNBR, PHI, QGEN, SYX, TIER, WEX, WILC Downgrades: ADES, AEGN, ARES, CVLT, ECOM, PSX, WES Initiations: WATT Read on to get TheStreet Quant Ratings' detailed report:

QIAGEN Receives U.S. FDA Approval For Cytomegalovirus (CMV) Testing On Automated QIAsymphony Platform

High-throughput application of artus CMV QS-RGQ MDx Kit on QIAsymphony streamlines critical and frequently performed viral infection test for transplant patients

Bristol-Myers Squibb And QIAGEN Sign Agreement For Use Of NGS Technology To Develop Gene Expression Profiles For Immuno-Oncology Therapies

Bristol-Myers Squibb Company (NYSE:BMY) and QIAGEN (NASDAQ:QGEN; Frankfurt Prime Standard:QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression...

QIAGEN Expands Biomarker Content Portfolio To Support Greater Use Of Molecular Diagnostics For Immuno-oncology Therapies

Option to add new biomarkers for microsatellite instability (MSI) and mismatch repair (MMR) to QIAGEN's NGS panels

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

New Research Suggests Potential For Additional Clinical Utility Of QIAGEN's QuantiFERON-TB Gold Plus

Findings indicate increased specificity in low-risk populations and potential for monitoring tuberculosis treatment

QIAGEN Expands Liquid Biopsy Pipeline With AR-V7 Test In Prostate Cancer

Exclusive license to RNA biomarker from The Johns Hopkins University clears path to commercialization

QIAGEN Joins CANCER-ID Consortium For Liquid Biopsy Workflows

Public-private partnership aims to standardize and clinically validate blood-based biomarkers

QIAGEN Launches First FDA-cleared JAK2 Test For Certain Type Of Leukemia

New biomarker test - the fifth QIAGEN oncology test with FDA clearance in the U.S. - designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Cytokinetics, Achillion and Qiagen were among the biotech stock movers in premarket trading on Thursday.

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEUA, BPMC, CAA, CAT, COMM, DAIO, DKS, EFII, HDS, HOG, ISTR, KEM, MSCC, MT, NWHM, QGEN, QLYS, TPRE Downgrades: COHU, DMD, EMN, GRC, SFS, SYNA, WWE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

3 Diversified Services Stocks Nudging The Industry Higher

3 Diversified Services Stocks Nudging The Industry Higher

TheStreet highlights 3 stocks pushing the diversified services industry higher today.

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) stock is jumping on Friday morning after the company posted earnings and revenue that topped analysts’ projections for the 2016 second quarter.

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Trade-Ideas LLC identified Qiagen (QGEN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Buy These 5 Stocks This Week for Breakout Gains

Buy These 5 Stocks This Week for Breakout Gains

These five technical setups are showing solid upside potential right now.

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.

Qiagen (QGEN) Weak On High Volume

Qiagen (QGEN) Weak On High Volume

Trade-Ideas LLC identified Qiagen (QGEN) as a weak on high relative volume candidate